Trial Profile
Phase II Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Oct 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Rituximab (Primary) ; Lenalidomide
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Therapeutic Use
- 18 Oct 2023 Planned End Date changed from 1 Mar 2025 to 31 Mar 2025.
- 18 Oct 2023 Planned primary completion date changed from 1 Mar 2025 to 31 Mar 2025.
- 22 Sep 2023 Planned End Date changed from 1 Nov 2023 to 1 Mar 2025.